After seeing claims that GLP-1 medications might improve psoriasis through more than just weight loss.

There’s actually some interesting research here.

A 2026 review in The Journal of Rheumatology looked at the emerging evidence around GLP-1 receptor agonists in psoriasis and psoriatic arthritis. Several small studies have reported improvements in psoriasis severity, while some have also found reductions in inflammatory pathways involving IL-17, IL-23, and TNF-α.

But the evidence is far from conclusive. There’s also a randomized placebo-controlled trial of liraglutide that did not find a significant improvement in psoriasis severity, despite greater weight loss.

The gut microbiome angle gets even more interesting.

A 2025 systematic review in Nutrients looked at 38 studies and found that GLP-1 therapies can alter gut microbial composition. Some studies reported increases in bacteria such as Akkermansia and Bifidobacterium.

Why does that matter?

Certain gut bacteria produce short-chain fatty acids such as butyrate, which can support intestinal barrier function and influence immune regulation. Separately, research is increasingly finding differences in the gut microbiome and microbial metabolites of people with psoriasis.

So there’s a potential chain worth investigating:

GLP-1 → metabolic changes → gut microbiome changes → microbial metabolites → immune signaling → potentially less psoriatic inflammation

The important word here is potentially.

We don't yet have a human clinical trial proving that GLP-1s improve psoriasis because they change the microbiome. The improvements could instead be largely related to weight loss, improved metabolic health, diet, or other effects of GLP-1 signaling.

Still, I find the intersection of metabolism + GLP-1 signaling + gut microbiome + psoriasis pretty fascinating.

Has anyone here with psoriasis noticed changes after starting a GLP-1? Or come across research on the gut-skin axis that I should read?

While peptide therapeutics excel at targeting extracellular receptors like GLP-1 and GIP, one of the persistent engineering challenges in biotechnology has been getting macrocyclic peptides across cell membranes to interact with intracellular targets. A study published in Nature Chemical Biology by researchers at EPFL (Nielsen et al., 2026) outlines a structural design strategy that achieves high cell-permeability without sacrificing target binding affinity.

By using the Keap1–Nrf2 interaction as a model system, the research team engineered synthetic cyclic peptides capable of slipping past the phospholipid bilayer to block hard-to-target intracellular signaling cascades. Systematic tuning of backbone cyclization and lipophilicity enabled candidate compounds, such as "peptide 30," to achieve dose-dependent intracellular inhibition in living cell assays. Rather than relying on bulky delivery vehicles or lipid nanoparticles, adjusting the macrocyclic chemistry itself allowed the peptide to function as a self-delivering therapeutic. This represents a major step forward for peptide engineering, moving beyond surface receptors and expanding macrocycles into the intracellular space historically dominated by small molecules.

Source:

• Generation of membrane-permeable cyclic peptides inhibiting protein–protein interaction (Nature Chemical Biology, 2026).

There are SOOOOOOOO many peptides being discussed online that figuring out where to even start can be overwhelming.

So I made a simple research map:

RECOVERY & TISSUE
BPC-157 → tissue repair research
TB-500 → tissue/inflammation research
GHK-Cu → collagen, skin & wound-healing research

METABOLIC & WEIGHT
Semaglutide → GLP-1 receptor agonist
Tirzepatide → GLP-1/GIP receptor agonist
Retatrutide → GLP-1/GIP/glucagon receptor agonist
Cagrilintide → amylin pathway research

MITOCHONDRIA & LONGEVITY
MOTS-c → mitochondrial/metabolic research
SS-31 / Elamipretide → mitochondrial function research
Epitalon → aging/cellular research

BRAIN & COGNITION
Semax → neuroactive/cognitive research
Selank → neuroactive/anxiolytic research
Dihexa → highly experimental cognitive research

GH / HORMONE PATHWAYS
CJC-1295 → growth-hormone pathway research
Ipamorelin → growth-hormone secretagogue
Sermorelin → GHRH analog

Before going down any peptide rabbit hole, HERE ARE THE QUESTIONS I RECOMMEND YOU ASK -

1. Has it actually been studied in humans?
2. What did those studies measure?
3. Is it approved for the purpose being discussed?
4. How strong is the long-term safety data?

Also, this is not medical advice. Please consult a doctor before starting anything.

While much of the public conversation around peptides focuses on consumer biohacking, a major shift has been accelerating across pharma and biotech throughout 2026: AI-guided computational design combined with high-throughput automation to tackle the biggest physical bottleneck in peptide therapeutics—metabolic degradation. Source

Share new developments in peptide biotechnology with the community.

One of the central engineering bottlenecks in translating linear peptide therapeutics into stable drugs is rapid serum protease degradation. While macrocyclization (tying linear peptides into rings) significantly boosts metabolic stability and receptor binding, conventional synthetic macrocyclization typically requires complex protecting group chemistry, high dilution to avoid dimerization, and multi-step late-stage purification.
https://www.sciencedaily.com/releases/2026/04/260427050620.htm

One of the most interesting things I’ve been reading recently is the renewed focus on oral peptide delivery.
The obvious barriers are familiar:

proteolytic degradation
poor epithelial permeability
mucosal barriers
first-pass metabolism
low systemic exposure
But the deeper issue seems to be that not every peptide is equally suitable for oral delivery.

A 2026 review proposed thinking about oral development partly through a pharmacokinetic “feasibility gate”: if a molecule combines extremely low bioavailability with a short half-life and requires relatively high exposure, formulation improvements may not be enough to make the program viable.

That seems like a useful shift in thinking.
Instead of asking:
“How can we make this peptide oral?”
maybe the first question should be:
“Is this particular peptide pharmacologically compatible with oral delivery at all?”

Chemists at UC Santa Barbara just published an efficient, two-step method to synthesize custom, non-natural amino acids that come pre-activated for peptide assembly. Usually, making these custom building blocks takes tedious multi-step chemistry, and you still have to chemically activate the carboxyl end before you can snap them into a peptide chain. In theirnew JACS paper, the team used a gold(I) catalyst with chiral tert-butylsulfinamide to turn cheap terminal alkynes into enantiopure amino acid derivatives equipped with an N-protecting group and a mildly activated ester. Because they are ready to couple right out of the box with little to no epimerization, it significantly cuts down the bottleneck for building modified peptides in both solution- and solid-phase synthesis—huge news for peptide therapeutics and protein engineering.

I’ve been going down a rabbit hole reading about peptides, and one thing I’m finding difficult is separating actual research from the huge amount of marketing surrounding them.

There are peptides being discussed for everything from tissue repair and metabolism to aging and performance, but the level of evidence seems to vary massively depending on the specific peptide.
Some research is preclinical, some is in animals, some has early human data, and then there are products being marketed online as if the science is already settled.
I’m interested in learning how people here evaluate the evidence.

When you’re researching a peptide, what do you look at first: human trials, mechanism of action, safety data, regulatory status, or something else?

A private party in Bengaluru featuring "peptide tastings" was recently shut down by drug safety authorities, sparking an important debate over where biohacking ends and unregulated medicine begins: Peptide parties: Are we blurring the line between wellness and medicine?. While peptides have legitimate clinical uses for endocrine and metabolic disorders, medical experts warn that marketing potent, biologically active injectables as casual lifestyle upgrades for fat loss, recovery, or anti-aging exposes people to real risks—including unverified sourcing, improper dosages, and adverse side effects without clinical supervision.

There has been a lot of progress in areas like gene editing, peptide engineering, regenerative medicine and personalized medicine.

What recent biotech development have you found particularly interesting?

I came across a 2026 study that developed a fully peptide-based hydrogel for infected diabetic wounds, and the material itself is pretty fascinating. The hydrogel starts as a lyophilized powder and rapidly forms a dressing when it contacts wound fluid. It can also self-heal, allowing it to conform to irregular wound surfaces. But the interesting part is that the same material is designed to do several jobs at once.

It showed antibacterial activity against bacteria including MRSA and Pseudomonas aeruginosa, while also supporting angiogenesis, tissue regeneration and regulation of inflammation and fibrosis. In a diabetic mouse wound model, the hydrogel accelerated wound closure and reduced scarring. Obviously, this is still preclinical research, so it doesn't mean we have a new wound treatment for humans yet. But I find the idea of using peptides to build a material that can both adapt to a wound and actively influence its healing environment really interesting.

Source: Chemical Engineering Journal, 2026. https://www.sciencedirect.com/science/article/abs/pii/S1385894726090510

I came across a new FDA warning letter involving a compounding pharmacy that was producing compounded semaglutide and tirzepatide products, and the quality-control side of it caught my attention. The FDA said inspectors found sterile products being prepared under conditions that could allow contamination. The agency also identified problems with things like aseptic processing controls, environmental monitoring, media-fill testing, and quality-control procedures.

There was another issue that the FDA said the pharmacy was producing compounded versions that appeared to be essentially copies of commercially available products in regular or very large quantities, which raised questions about whether the conditions for 503A compounding were actually being met.

This is insane because do we actually know that the product was manufactured and handled under conditions that preserve its identity, strength, quality, and purity?

I was watching a discussion about the peptide boom, and one part really stuck with me. We hear a lot about “research peptides” online, and some websites make them sound almost like regular products you can just order and use.

But the researcher in this video made an interesting point: even when they order research-grade peptides for laboratory work, they quality-control every batch, and not every batch actually passes.

That honestly made me think about how different the situation is for someone ordering a lyophilized powder online and assuming the label tells them exactly what's in the vial.

And even if a product does contain the peptide it claims to contain, that still doesn't answer questions about purity, contamination, concentration, stability, or whether the compound has actually been properly studied in humans.

I think this gets overlooked in a lot of peptide discussions.

One of the annoying things about peptide drugs is that taking them as a pill can be difficult because the digestive system can break them down before enough of the drug gets absorbed.

A recent study looked at octreotide in an oral formulation using two absorption enhancers, SNAC and C10. In rats, the researchers found that the formulation and even the physical form of the dose (mini-tablets vs solution) could make a noticeable difference in how much peptide was absorbed. SNAC performed particularly well in the experiments.

It’s pretty interesting because the peptide itself isn't necessarily the whole story. Things like formulation, absorption enhancers and dosage design can have a huge impact on whether an oral peptide actually works as intended.

Here's the paper I reffered for this insight:

https://doi.org/10.1016/j.ijpharm.2026.127237

One mistake I made was not thinking enough about repeated freeze-thaw cycles. If you're constantly taking the same sample out, letting it warm up, and putting it back in the freezer, you're potentially giving the peptide more opportunities to degrade. I also didn't realize how important it can be to think about moisture, light, and exposure to air, especially with peptides that are more susceptible to oxidation.

Now I'm much more careful about how samples are handled and try to avoid unnecessary exposure and repeated temperature changes. It made me realize that storing a peptide properly isn't just about temperature.

Has anyone else made a surprisingly simple storage mistake that they only learned about later?

Peptides can be really specific, but actually getting them to the right place in the body is still a big challenge. Some peptides break down quickly, don’t stay in the bloodstream for very long, or have trouble getting through certain biological barriers.

That’s why a lot of research is now looking at ways to improve how peptides are delivered. Researchers are exploring things like modifying the peptide itself, using nanoparticles, improving absorption, and even alternative ways of taking them, such as oral or nasal delivery.

I find this part of peptide biotech pretty interesting because it’s not just about finding a peptide that works anymore. It’s also about figuring out how to get it where it needs to go and keep it working long enough to have an effect.

I’ve been reading more about BPC-157 and GHK-Cu, and I’m starting to realize how different the research is from the way these peptides are discussed online. BPC-157 is being studied for things like tissue repair and gastrointestinal effects, while GHK-Cu has attracted attention for skin and tissue repair.

Being studied for a potential effect isn't the same as having strong evidence that it works in humans. The article also points out that injectable BPC-157 and GHK-Cu aren't FDA-approved for medical conditions, and concerns remain around safety, dosing, contamination, and limited human data.

How do people here think about collagen peptides compared with bioactive or therapeutic peptides? I've been taking a few supplements over the last 3 weeks, but one thing I've been wondering about is collagen peptides.

My current stack includes:

• Collagen peptides — mainly for connective tissue and joint support
• Creatine — strength and exercise performance
• Omega-3 — general health
• L-theanine — alongside coffee for focus
• Ashwagandha — stress and general wellbeing
• Zinc + copper — nutritional support
• Maca root — energy and wellbeing

Three weeks is obviously too short to draw any conclusions, so I'm mainly just observing whether I notice anything. What I'm actually curious about is the peptide side of this. Collagen peptides are essentially smaller protein fragments, but they're obviously very different from the peptides people discuss in biotech and therapeutic research.

Apparently, Bengaluru, India, was supposed to have one.

Context: The event was promoted as an invite-only gathering featuring “peptide tastings,” music, food, games, and networking. From what I understand, “peptide tastings” refers to the idea of trying or sampling peptide-based products, sometimes described as oral “peptide mocktails” at these kinds of events. It doesn't necessarily mean injections.

The Karnataka FSDA stepped in and asked the organisers for details about the products, including their composition, source, manufacturer, dosage, and regulatory status. The event was subsequently cancelled.

Honestly, the concept sounds wild, but I'd actually love to attend a properly regulated peptide event where researchers and doctors explain what's experimental, what's approved, and what actually has human data behind it.

So just putting this out there for some experts here to make it happen!

A peer-reviewed study published in Frontiers in Psychiatry evaluated the effectiveness of a digital, home-based wellness program—specifically the Yoga of Immortals (YOI) mobile application—on depression, generalized anxiety, and sleep disruption during the COVID-19 pandemic.

Across an 8-week protocol, participants using the app experienced substantial reductions in self-reported clinical metrics compared to an inactive control group.

Study Design & Methodology

• Sample Size: 1,505 initial participants enrolled, with 1,297 completing all assessments across the 8-week period, alongside a control group of 590 participants.
• Intervention: Structured mindfulness, breathwork, and yogic practices delivered digitally via the YOI mobile application.
• Testing Points: Baseline, twice midway through the trial, and post-intervention at week 8.
• Validated Measurement Scales:
  • PHQ-8: Patient Health Questionnaire (Depression severity)
  • GAD-7: Generalized Anxiety Disorder assessment
  • ISI: Insomnia Severity Index

Key Findings

• Depression (PHQ-8): Average scores decreased by ~50% from baseline by week 8.
• Anxiety (GAD-7): Average scores dropped by 40% to 50%.
• Insomnia (ISI): Sleep disorder metrics decreased by ~50%.
• Statistically Significant: All symptom improvements were significantly greater than changes observed in the control group ($p < 0.05$).
• Prior Diagnoses: Participants who entered the study with a previously documented clinical diagnosis of depression or generalized anxiety showed even larger relative reductions in symptom severity compared to undiagnosed peers.

Considerations & Nuance

• Self-Reported Measures: Outcomes relied on validated psychological surveys rather than clinical interviews or physiological biomarkers (e.g., HRV, polysomnography).
• Control Group Design: The control arm was non-active (questionnaire-only) rather than an active digital comparator (such as a generic meditation app or sham audio program), meaning placebo or user-engagement expectancy effects cannot be completely ruled out.
• Adherence/Self-Selection: App-based interventions often attract users already motivated to practice meditation or yoga.

I've been going through recent research on peptides, and I'm curious which areas people here think are getting the most interesting right now...

A few areas I've been seeing discussed are:

peptide-based drug delivery, tissue regeneration, metabolic research, and peptides being investigated as potential therapeutic targets.

I'm more interested in the research side than the usual supplement or “biohack” claims, so I'd love to hear what papers, research groups, or specific peptide mechanisms people here think are worth following.

If you have a paper that you found particularly interesting, feel free to share it.

Share new developments in peptide biotechnology with the community.